BM
Phase 2/3 Completed
492 enrolled
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Phase 1 Completed
22 enrolled
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Phase 2 Completed
44 enrolled 16 charts
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1 Completed
19 enrolled
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
115 enrolled 11 charts
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
92 enrolled 24 charts
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Phase 2 Completed
66 enrolled 8 charts
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase 1/2 Completed
136 enrolled 27 charts
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
110 enrolled
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase 1/2 Completed
11 enrolled 6 charts
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Phase 1/2 Completed
62 enrolled 15 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Phase 2 Completed
69 enrolled
AVF4120s
Phase 2 Completed
74 enrolled 7 charts
Ph I Dasatinib + Erlotinib in Recurrent MG
Phase 1 Completed
47 enrolled
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Phase 2 Completed
110 enrolled
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Phase 2 Completed
32 enrolled 13 charts
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Phase 2 Completed
171 enrolled
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Phase 2 Completed
57 enrolled 16 charts
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
27 enrolled
Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer
Phase 1 Completed
11 enrolled